Ekso Bionics (NASDAQ:EKSO) Issues Earnings Results

Ekso Bionics (NASDAQ:EKSO) issued its quarterly earnings data on Monday. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04), Yahoo Finance reports. The company had revenue of $3.76 million for the quarter, compared to the consensus estimate of $4.99 million. Ekso Bionics had a negative return on equity of 95.36% and a negative net margin of 79.48%. During the same period in the prior year, the firm posted ($0.33) earnings per share.

Ekso Bionics Price Performance

Shares of NASDAQ EKSO opened at $1.28 on Thursday. Ekso Bionics has a twelve month low of $0.62 and a twelve month high of $3.13. The stock’s 50 day moving average price is $1.46 and its 200-day moving average price is $1.63. The company has a market capitalization of $23.17 million, a PE ratio of -1.31 and a beta of 1.63. The company has a quick ratio of 1.87, a current ratio of 2.81 and a debt-to-equity ratio of 0.33.

Analyst Upgrades and Downgrades

EKSO has been the subject of a number of recent research reports. StockNews.com raised Ekso Bionics from a “sell” rating to a “hold” rating in a report on Thursday, April 4th. HC Wainwright boosted their price objective on Ekso Bionics from $9.25 to $10.00 and gave the stock a “buy” rating in a report on Tuesday.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.